Comparative evaluation of the clinical and radiographic efficacy of 0.05% zoledronate gel as local drug delivery system in treating intrabony defects in stage III grade B periodontitis patients with and without type‐2 diabetes mellitus—A randomized split‐mouth clinical trial
Clinical Advances in Periodontics · 2024
DOI: 10.1002/cap.10262 ↗At a glance
Randomisierte kontrollierte Studie in Clinical Advances in Periodontics, 2024. Written by Subash Chandra Raj and 6 co-authors. Institution: Department of Periodontics, S.C.B Dental College and Hospital, Cuttack, Odisha, India. Major MEDLINE topics: Diabetes Mellitus, Type 2, Alveolar Bone Loss, Gels, Zoledronic Acid. Cited 7 times so far (Crossref); 55 references.
Topics: Diabetes mellitus
Abstract (original language)
Background
This 6‐month randomized split‐mouth and placebo‐controlled clinical trial aimed to evaluate the clinical and radiographic efficacy of adjunctive use of 0.05% zoledronate (ZLN) gel as local drug delivery to scaling and root planing (SRP) in stage III, grade B periodontitis patients with and without controlled type‐2 diabetes mellitus (DM).
Methods
A total of 120 infrabony sites were divided into two groups: Group‐1 (non‐diabetic periodontitis) and Group‐2 (periodontitis + DM). A total of 60 sites in each group were randomized to receive treatment with SRP + placebo gel (control) or SRP + 0.05% ZLN gel (test). Plaque index (PI), modified sulcus bleeding index (mSBI), pocket probing depth (PPD), and relative attachment levels (RAL) were assessed at baseline, 3 and 6 months, and digital intraoral periapical and cone‐beam computed tomography imaging were used to measure the linear and percentage reduction of intrabony defect depth (DD, DDR%) after 6 months.
Results
Group‐1 showed significant reduction in PI (0.56 ± 0.15 and 0.52 ± 0.19 from 0.67 ± 0.17), mSBI (0.7 ± 0.60 and 0.47 ± 0.57 from 0.9 ± 0.48), PPD (4.6 ± 0.85 and 3.43 ± 0.63 from 6.5 ± 1.04) and gain in RAL (7.03 ± 0.85 and 5.93 ± 0.69 from 8.9 ± 1.09) in the ZLN‐treated sites than the placebo sites and also from Group‐2 sites after 3 and 6 months, respectively. A significant reduction in DD of 28.79% in Group‐1 and 22.20% in Group‐2 at ZLN sites was seen compared to placebo sites of both groups.
Conclusion
ZLN gel applied subgingivally in infrabony pockets resulted in significant clinical improvements evident by probing depth reduction and gain in attachment levels along with radiographic evidence of more bone fill seen in non‐diabetic patients compared to diabetic periodontitis patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Periodontics, S.C.B Dental College and Hospital, Cuttack, Odisha, India.
- School of Pharmaceutical Sciences, Siksha-O-Anusandhan, Deemed to be University, Bhubaneswar, Odisha, India.
ORCID profiles: Subash Chandra Raj, Asit Kumar Mishra, Devapratim Mohanty, Neelima Katti, Snigdha Pattnaik, Laxmikanta Patra
Cite
APA
Raj, S. C., Mishra, A. K., Mohanty, D., Katti, N., Pattnaik, S., Patra, L., & Pattanaik, A. (2024). Comparative evaluation of the clinical and radiographic efficacy of 0.05% zoledronate gel as local drug delivery system in treating intrabony defects in stage III grade B periodontitis patients with and without type‐2 diabetes mellitus—A randomized split‐mouth clinical trial. Clinical Advances in Periodontics. https://doi.org/10.1002/cap.10262
Vancouver
Raj SC, Mishra AK, Mohanty D, Katti N, Pattnaik S, Patra L, et al. Comparative evaluation of the clinical and radiographic efficacy of 0.05% zoledronate gel as local drug delivery system in treating intrabony defects in stage III grade B periodontitis patients with and without type‐2 diabetes mellitus—A randomized split‐mouth clinical trial. Clinical Advances in Periodontics. 2024. doi:10.1002/cap.10262
BibTeX
@article{Raj2024,
author = {Raj, Subash Chandra and Mishra, Asit Kumar and Mohanty, Devapratim and Katti, Neelima and Pattnaik, Snigdha and Patra, Laxmikanta and Pattanaik, Abinash},
title = {Comparative evaluation of the clinical and radiographic efficacy of 0.05% zoledronate gel as local drug delivery system in treating intrabony defects in stage III grade B periodontitis patients with and without type‐2 diabetes mellitus—A randomized split‐mouth clinical trial},
journal = {Clinical Advances in Periodontics},
year = {2024},
doi = {10.1002/cap.10262}
}
EUVIMED